IT Advisory and Fractional CIO Services for Life Sciences
Life sciences organizations make technology decisions at every stage that are difficult and expensive to reverse, and most are made without the regulatory depth or strategic experience that a GxP environment demands.
GxP IT Advisory for Regulated Biotech and Life Sciences
Fractional CIO and CDO Advisory
Senior IT Leadership Available When You Need It
Most life sciences organizations at Series A through pre-commercial stage are making technology decisions that require CIO-level expertise they don't yet have in-house. Hiring a full-time CIO takes six to nine months and costs upwards of $300,000 per year before equity. A fractional CIO brings the same strategic depth, available within weeks.
Where we advise:
Technology strategy aligned to funding rounds and clinical milestones
Trade-offs between speed, cost, and compliance
Build vs buy decisions across core platforms
Vendor selection and governance
M&A technical diligence and integration strategy
Outcome
Senior IT leadership that strengthens investor confidence, avoids costly architectural mistakes, and establishes a scalable technology foundation at a fraction of the cost of a full-time hire.
GxP Cloud Architecture and Strategy
Cloud Infrastructure Built for Regulatory Audit
Cloud decisions made for speed and convenience, without accounting for validation overhead and long-term scalability, create compliance debt that surfaces at the worst possible times. We design AWS and Azure environments for life sciences with audit-readiness built into the foundation, using Infrastructure-as-Code governance and validated landing zones from day one.
Where we advise:
AWS and Azure architecture for GxP environments
Infrastructure-as-Code strategy and governance
Shared responsibility modelling and risk ownership
Life sciences cloud migration strategy from legacy to validated systems
Cost-performance optimization for regulated environments
Outcome
Audit-ready cloud infrastructure with full compliance coverage between the platform layer and the applications it supports.
Pharmacovigilance and Safety Systems Strategy
PV Modernization with Compliance Integrity Preserved
Pharmacovigilance system modernization carries significant compliance risk when treated as a standard IT migration. We advise on PV transformation with full audit lineage, validated migration paths, and AI-assisted signal detection capabilities that meet EMA and FDA expectations.
Where we advise:
Target architecture for pharmacovigilance and safety systems
Migration strategy with full audit lineage preserved
AI-enabled case processing and signal detection
Vendor and platform selection with compliance evaluation
Outcome
Modernized PV capability with improved reporting speed and data quality, without the compliance exposure that poorly managed migrations generate.
Digital and Data Transformation Strategy
Connected Systems That Support Scientific and Operational Performance
Fragmented systems and manual processes slow life sciences organizations down at precisely the stages where operational speed matters most. We advise on integration strategy and data architecture that improves decision-making across LIMS, ELN, QMS, and MES environments, with a clear roadmap through legacy system rationalization.
Where we advise:
Integration strategy across LIMS, ELN, QMS, and MES
Data architecture and interoperability design
Workflow automation opportunities
Legacy system rationalization roadmap
Outcome
Reduced fragmentation and manual overhead, with improved data accessibility and faster decision-making across scientific and operational functions.
Cybersecurity and Resilience Strategy
Protecting IP, Patient Data and Trial Integrity
Cybersecurity decisions in life sciences carry regulatory and business consequences that go beyond the standard enterprise risk framework. IP protection, patient data security, and trial data integrity all carry audit and regulatory implications. We design security architectures aligned to GxP risk frameworks, with resilience and disaster recovery strategies built to hold up under both regulatory scrutiny and real-world pressure.
Where we advise:
Security architecture including zero trust, identity, and access management
Risk-based control frameworks aligned to GxP requirements
Resilience and disaster recovery strategy
Governance and monitoring models
Outcome
Reduced regulatory and operational risk, with critical assets and data protected and business continuity assured.
IT Program Management and Delivery
Program Leadership That Keeps Compliance and Delivery Aligned
Programs fail when execution drifts from the strategy and compliance requirements that shaped the original decisions. We embed experienced program and project leaders who bring both delivery discipline and GxP regulatory literacy to your initiatives, keeping complex implementations on track without generating the compliance exposure that poorly governed IT PMO programs create.
Where we advise and lead:
Portfolio prioritization aligned to business milestones
Program governance and risk management
Vendor coordination and accountability
Integration across IT, quality, clinical, and operations
Outcome
Predictable, milestone-driven delivery with compliance embedded throughout rather than reviewed at the end.
GxP IT Advisory That Is Decision-Centered and Execution-Backed
We Focus on Decisions Not Just Delivery
We help you make the right technology calls before execution begins, which is where the long-term outcome is determined.
GxP-Literate Technology Advisory
Every recommendation is designed with regulatory impact in mind, covering 21 CFR Part 11, Annex 11, GAMP 5, and the validation implications of cloud and AI decisions.
Fractional and Consistent
Senior IT leadership without the cost, hiring timeline, or turnover risk of a full-time hire, available when you need it and scaled to your stage.
Modern Technology Depth
We advise on cloud, AI, and data platforms built for how regulated life sciences organizations operate today, not legacy IT frameworks that no longer reflect that reality.
Execution Accountability
We stay involved through delivery to make sure decisions translate into outcomes.
Built for Leaders Making Technology Decisions with Long-Term Consequences
CEO and Founder
Technology decisions that support valuation, investor confidence, and operational scale from preclinical through commercial.
CTO and CIO
Systems architecture that holds up under compliance scrutiny and scales with the business as clinical and commercial stages advance.
VP Quality Assurance
IT decisions that align with inspection expectations and don't generate validation surprises at critical milestones.
COO and VP Operations
Infrastructure that supports clinical, manufacturing, and commercial readiness at each stage of growth.
When to engage
- Series A or B scaling and platform build-out
- Preparing for IND, clinical trials, or commercialization
- Transitioning from research tools to GxP systems
- M&A diligence or investor technical scrutiny
- Cloud, AI, or pharmacovigilance system modernization
Frequently asked questions.
01What is a fractional CIO and when should a life sciences organization consider one?
A fractional CIO provides executive-level technology leadership on a part-time or interim basis. It is the right model when your organization is making decisions that require CIO-level expertise but isn't yet at the stage where a full-time hire makes financial or operational sense.
02How is GxP IT advisory different from standard IT consulting?
We focus on the decisions, trade-offs, and long-term architectural outcomes that determine what your technology environment looks like in three years, alongside the regulatory implications of each choice, rather than just the implementation task directly in front of you.
03When is the right time to engage IT advisory support?
Before major decisions: system selection, cloud architecture, AI adoption, scaling infrastructure, or entering a new clinical or commercial stage. The earlier in the decision cycle, the more value advisory contributes.
04How do you ensure alignment with GxP regulatory requirements?
All recommendations are designed with GxP compliance in mind from the first conversation, covering cloud architectures that account for audit-readiness, system selections that consider validation overhead, and IT roadmaps that reflect the compliance implications of each decision.
05What are the most common IT mistakes at Series A and B stage in life sciences?
Selecting systems that don't scale to GxP requirements, building cloud environments that require costly remediation before audit, and under-resourcing IT leadership at precisely the stage when the most consequential decisions are being made.
What Technology Decisions Are You Making Today That You Will Need to Defend Tomorrow?
Our team will give you an honest assessment of your current technology position and the most practical path forward.
Explore our other disciplines